BIOA
BioAge Labs, Inc.
Biotechnology
Market Cap$641M
5Y Perf.-14.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BIOA vs VNDA
Revenue, margins, valuation, and 5-year total return — side by side.
VNDA
Vanda Pharmaceuticals Inc.
Biotechnology
Market Cap$378M
5Y Perf.+36.2%
BIOA vs VNDA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BIOA | VNDA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $641M | $378M |
| Revenue (TTM) | $9M | $218M |
| Net Income (TTM) | $-81M | $-240M |
| Gross Margin | 99.2% | 71.1% |
| Operating Margin | -10.3% | -73.6% |
| Total Debt | $6M | $13M |
| Cash & Equiv. | $189M | $85M |
BIOA vs VNDA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BIOA
VNDA
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | 100 | 85.7 | -14.3% |
| Vanda Pharmaceutica… (VNDA) | 100 | 136.2 | +36.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BIOA vs VNDA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: VNDA leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. BioAge Labs, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
BIOA
BioAge Labs, Inc.
The Growth Play
BIOA is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth 66.2%
- -2.7% 10Y total return vs VNDA's -26.8%
- Lower volatility, beta 1.41, Low D/E 2.0%, current ratio 14.24x
Best for: growth exposure and long-term compounding
VNDA
Vanda Pharmaceuticals Inc.
The Income Pick
VNDA carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- beta 1.04
- Beta 1.04, current ratio 2.39x
- 8.7% revenue growth vs BIOA's -13.3%
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | VNDA | 8.7% revenue growth vs BIOA's -13.3% |
| Quality / Margins | VNDA | -110.0% margin vs BIOA's -9.0% |
| Stability / Safety | VNDA | Beta 1.04 vs BIOA's 1.41 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | BIOA | +338.9% vs VNDA's +45.9% |
| Efficiency (ROA) | BIOA | -25.5% ROA vs VNDA's -44.6%, ROIC -210.2% vs -32.2% |
BIOA vs VNDA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
BIOA vs VNDA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBIOALAGGINGVNDA
VNDAVanda Pharmaceuticals…
2leads
BIOABioAge Labs, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs VNDAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
VNDA3/5
Valuation MetricsMultiples, price ratios, and targets
VNDA2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BIOA7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
BIOA6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
VNDA leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
VNDA is the larger business by revenue, generating $218M annually — 24.2x BIOA's $9M. Profitability is closely matched — net margins range from -110.0% (VNDA) to -9.0% (BIOA).
| Metric | BIOABioAge Labs, Inc. | VNDAVanda Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $9M | $218M |
| EBITDAEarnings before interest/tax | -$93M | -$150M |
| Net IncomeAfter-tax profit | -$81M | -$240M |
| Free Cash FlowCash after capex | -$82M | -$127M |
| Gross MarginGross profit ÷ Revenue | +99.2% | +71.1% |
| Operating MarginEBIT ÷ Revenue | -10.3% | -73.6% |
| Net MarginNet income ÷ Revenue | -9.0% | -110.0% |
| FCF MarginFCF ÷ Revenue | -9.2% | -58.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +3.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +63.5% | -64.0% |
VNDA leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
VNDA leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | BIOABioAge Labs, Inc. | VNDAVanda Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $641M | $378M |
| Enterprise ValueMkt cap + debt − cash | $458M | $305M |
| Trailing P/EPrice ÷ TTM EPS | -7.96x | -1.71x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 71.28x | 1.75x |
| Price / BookPrice ÷ Book value/share | 2.35x | 1.15x |
| Price / FCFMarket cap ÷ FCF | — | — |
VNDA leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
BIOA leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
BIOA delivers a -27.9% return on equity — every $100 of shareholder capital generates $-28 in annual profit, vs $-61 for VNDA. BIOA carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to VNDA's 0.04x. On the Piotroski fundamental quality scale (0–9), BIOA scores 5/9 vs VNDA's 2/9, reflecting solid financial health.
| Metric | BIOABioAge Labs, Inc. | VNDAVanda Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | -27.9% | -61.4% |
| ROA (TTM)Return on assets | -25.5% | -44.6% |
| ROICReturn on invested capital | -2.1% | -32.2% |
| ROCEReturn on capital employed | -30.7% | -33.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 0.04x |
| Net DebtTotal debt minus cash | -$183M | -$72M |
| Cash & Equiv.Liquid assets | $189M | $85M |
| Total DebtShort + long-term debt | $6M | $13M |
| Interest CoverageEBIT ÷ Interest expense | -118.34x | — |
BIOA leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
BIOA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BIOA five years ago would be worth $9,732 today (with dividends reinvested), compared to $3,578 for VNDA. Over the past 12 months, BIOA leads with a +338.9% total return vs VNDA's +45.9%. The 3-year compound annual growth rate (CAGR) favors BIOA at -0.9% vs VNDA's -2.7% — a key indicator of consistent wealth creation.
| Metric | BIOABioAge Labs, Inc. | VNDAVanda Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | +38.9% | -22.5% |
| 1-Year ReturnPast 12 months | +338.9% | +45.9% |
| 3-Year ReturnCumulative with dividends | -2.7% | -7.8% |
| 5-Year ReturnCumulative with dividends | -2.7% | -64.2% |
| 10-Year ReturnCumulative with dividends | -2.7% | -26.8% |
| CAGR (3Y)Annualised 3-year return | -0.9% | -2.7% |
BIOA leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BIOA and VNDA each lead in 1 of 2 comparable metrics.
Risk & Volatility
VNDA is the less volatile stock with a 1.04 beta — it tends to amplify market swings less than BIOA's 1.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BIOA currently trades 74.3% from its 52-week high vs VNDA's 64.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BIOABioAge Labs, Inc. | VNDAVanda Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.41x | 1.04x |
| 52-Week HighHighest price in past year | $24.00 | $9.94 |
| 52-Week LowLowest price in past year | $3.67 | $3.81 |
| % of 52W HighCurrent price vs 52-week peak | +74.3% | +64.3% |
| RSI (14)Momentum oscillator 0–100 | 55.2 | 54.9 |
| Avg Volume (50D)Average daily shares traded | 464K | 1.6M |
Evenly matched — BIOA and VNDA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BIOA as "Buy" and VNDA as "Buy". Consensus price targets imply 152.5% upside for BIOA (target: $45) vs 121.8% for VNDA (target: $14).
| Metric | BIOABioAge Labs, Inc. | VNDAVanda Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $45.00 | $14.17 |
| # AnalystsCovering analysts | 3 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
VNDA leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). BIOA leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallBioAge Labs, Inc. (BIOA)Leads 2 of 6 categories
Loading custom metrics...
BIOA vs VNDA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BIOA or VNDA a better buy right now?
Analysts rate BioAge Labs, Inc.
(BIOA) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BIOA or VNDA?
Over the past 5 years, BioAge Labs, Inc.
(BIOA) delivered a total return of -2. 7%, compared to -64. 2% for Vanda Pharmaceuticals Inc. (VNDA). Over 10 years, the gap is even starker: BIOA returned -2. 7% versus VNDA's -26. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BIOA or VNDA?
By beta (market sensitivity over 5 years), Vanda Pharmaceuticals Inc.
(VNDA) is the lower-risk stock at 1. 04β versus BioAge Labs, Inc. 's 1. 41β — meaning BIOA is approximately 36% more volatile than VNDA relative to the S&P 500. On balance sheet safety, BioAge Labs, Inc. (BIOA) carries a lower debt/equity ratio of 2% versus 4% for Vanda Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BIOA or VNDA?
On earnings-per-share growth, the picture is similar: BioAge Labs, Inc.
grew EPS 66. 2% year-over-year, compared to -1068. 8% for Vanda Pharmaceuticals Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BIOA or VNDA?
Vanda Pharmaceuticals Inc.
(VNDA) is the more profitable company, earning -102. 0% net margin versus -896. 1% for BioAge Labs, Inc. — meaning it keeps -102. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VNDA leads at -70. 0% versus -1031. 5% for BIOA. At the gross margin level — before operating expenses — BIOA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BIOA or VNDA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BIOA or VNDA better for a retirement portfolio?
For long-horizon retirement investors, Vanda Pharmaceuticals Inc.
(VNDA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04)). Both have compounded well over 10 years (VNDA: -26. 8%, BIOA: -2. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BIOA and VNDA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.